Zealand Pharma Shares Drop Over 25% After New Safety Data Raises Concerns
Shares of Zealand Pharma (ZEPH.CO) fell as much as 26% after new safety data on its experimental weight-loss drug, survodutide, raised concerns over side effects. The high discontinuation rate due to gastrointestinal issues could limit the drug's commercial potential.
Topics: clinical_trial_results obesity_treatment pharmaceuticals side_effects